Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 60.29 Million EUR | -0.41% |
| 2022 | 60.53 Million EUR | 83.58% |
| 2021 | 32.97 Million EUR | 36.35% |
| 2020 | 24.18 Million EUR | 487.87% |
| 2019 | 4.11 Million EUR | 103.97% |
| 2018 | 2.01 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 63.19 Million EUR | -1.65% |
| 2024 Q2 | 64.25 Million EUR | 7.7% |
| 2024 Q1 | 59.66 Million EUR | -1.04% |
| 2023 FY | 60.29 Million EUR | -0.41% |
| 2023 Q3 | 68.22 Million EUR | 1.57% |
| 2023 Q4 | 60.29 Million EUR | -11.63% |
| 2023 Q2 | 67.17 Million EUR | 4.1% |
| 2023 Q1 | 64.52 Million EUR | 6.58% |
| 2022 Q4 | 60.53 Million EUR | -2.88% |
| 2022 FY | 60.53 Million EUR | 83.58% |
| 2022 Q3 | 62.33 Million EUR | 21.44% |
| 2022 Q2 | 51.33 Million EUR | 30.0% |
| 2022 Q1 | 39.48 Million EUR | 19.74% |
| 2021 Q2 | 28.16 Million EUR | 5.1% |
| 2021 Q4 | 32.97 Million EUR | 7.74% |
| 2021 Q3 | 30.6 Million EUR | 8.67% |
| 2021 FY | 32.97 Million EUR | 36.35% |
| 2021 Q1 | 26.79 Million EUR | 10.81% |
| 2020 FY | 24.18 Million EUR | 487.87% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 24.18 Million EUR | 0.0% |
| 2019 FY | 4.11 Million EUR | 103.97% |
| 2018 FY | 2.01 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AroCell AB (publ) | 6.07 Million SEK | -893.098% |
| Devyser Diagnostics AB (publ) | 20.6 Million SEK | -192.675% |
| Immunovia AB (publ) | 1.00 SEK | -6029099900.0% |
| Prostatype Genomics AB (publ) | 203 Thousand SEK | -29600.0% |
| SenzaGen AB | 6.22 Million SEK | -868.064% |
| Spermosens AB | -232 Thousand SEK | 26087.5% |